Skip to main content
KYONGBO PHARMACEUTICAL CO., LTD. logo

KYONGBO PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 214390 ISIN · KR7214390007 LEI · 988400YKOM1CHDS6R917 KO Manufacturing
Open in API
Filings indexed 206 across all filing types
Latest filing 2024-12-27 Regulatory Filings
Country KR South Korea
Listing KO 214390

About KYONGBO PHARMACEUTICAL CO., LTD.

https://www.kbpharma.co.kr/en/home

Kyongbo Pharmaceutical Co., Ltd. is a pharmaceutical company specializing in the research, development, and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished drug products. The company also operates as a Contract Development and Manufacturing Organization (CDMO), offering integrated services from early-stage development through to commercial cGMP production. Its core product portfolio includes a diverse range of APIs, such as sterile and non-sterile cephalosporins, carbapenem antibiotics, and high-potency cytotoxic anti-cancer agents. In addition to APIs, the company manufactures finished dosage forms, including solid oral medications and sterile injectables. Kyongbo Pharmaceutical utilizes dedicated and segregated manufacturing facilities to produce its specialized product lines, supported by a strong commitment to research and innovation in API synthesis.

Recent filings

Filing Released Lang Actions
매매거래정지및정지해제(풍문등조회공시)
Regulatory Filings Classification · 100% confidence The document is a short regulatory notice from the Korea Exchange regarding the suspension and resumption of trading for Kyongbo Pharmaceutical due to a request for disclosure (rumors). It is a standard regulatory announcement regarding market operations and does not fit into specific categories like earnings, dividends, or annual reports. Therefore, it falls under the fallback category for regulatory announcements.
2024-12-27 Korean
가족친화인증ㆍ유효기간연장ㆍ인증취소(자율공시)
Environmental & Social Information Classification · 100% confidence The document is a voluntary disclosure (자율공시) regarding the extension of a 'Family-Friendly Certification' issued by the Ministry of Gender Equality and Family. It details the certification status, validity period, and the company's internal policies related to work-life balance. Since this is a regulatory announcement regarding corporate governance/social certification status that does not fit into specific financial reporting categories like 10-K or IR, it is classified as a general regulatory filing.
2024-12-18 Korean
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory announcement from Kyongbo Pharmaceutical regarding the setting of a record date for shareholder rights (dividend eligibility). It explicitly states that this is not the final dividend declaration, but rather a procedural step to establish the record date for future dividend decisions. This fits the definition of a regulatory announcement regarding corporate actions, and since it does not announce the dividend amount itself, it is best classified as a general regulatory filing.
2024-12-16 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement from Kyungbo Pharmaceutical regarding the setting of a record date and shareholder register closure period for the purpose of the 38th Annual General Meeting. It does not contain the full report or proxy materials themselves, but rather serves as a formal regulatory notice of an upcoming corporate event. Given the nature of the announcement, it fits best under the general regulatory filing category.
2024-12-16 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the 38th fiscal period, covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial and operational information, including company overview, business activities, capital structure, and product performance. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. 9M 2024
2024-11-14 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Provisional Earnings Release' (영업(잠정)실적) for Kyongbo Pharmaceutical for the third quarter of 2024. It provides key financial highlights such as revenue, operating profit, and net income, comparing them to previous periods. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results. Q3 2024
2024-10-25 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.